Markets Nosedive
Sensex loses 388 points, Nifty ends below 6,000 on Fed, China concerns
The Nifty posted its biggest percentage fall in a year on Thursday, as the prospect of an end to the U.S. stimulus programme and a weak China manufacturing survey sparked concerns foreign investors would end their recent buying spree. Full Article
REUTERS SHOWCASE
Buy, Sell or Hold?
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Bayer files suit against Lupin over plans for generic pill
Track Markets: BSE Sectoral Indices
Track and analyse performance of all BSE sectoral indices and other global indices on a single page. Full Coverage
A pharmacist counts pills in a pharmacy in Toronto in this January 31, 2008 file photo.
Credit: Reuters/Mark Blinch/Files
FRANKFURT |
FRANKFURT (Reuters) - German drugmaker Bayer(BAYGn.DE) has filed a suit in the United States against Indian generic drug maker Lupin(LUPN.NS), to prevent it from selling a version of Bayer's birth-control pill Natazia there.
In the lawsuit, filed on November 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.
The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sale of the alleged copied product.
Lupin was not immediately available for comment.
Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.
Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.
Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware.
(Reporting by Ludwig Burger and Marilyn Gerlach; Editing by Elaine Hardcastle)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Ludwig Burger, Marilyn Gerlach; & Elaine Hardcastle
I wonder why the Lupin comment has not been included in the story inspite of us having responded to your correspondent’s request in less than ten minutes.
Lupin not being availaible for comment is untrue and you publishing this story inpite of us havin send our statment very incorrect reporting.
Shamsher Gorawara
Head, Corporate Communications
Lupin Limited
shamshergorawara@lupinpharma.com
Handy No: +91-9820338555
Follow Reuters